Peking University Third Hospital
北京大学第三医院
Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Peking University Third Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatocellular carcinoma肝细胞癌11 papers led1 open trial led
- Stomach cancer胃癌24 papers led2 open trials led
- Chordoma脊索瘤6 papers led
- Osteosarcoma骨肉瘤7 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
- Neuroblastoma神经母细胞瘤0 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤5 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Haemophilia A血友病 A1 paper led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
- IgG4-related diseaseIgG4相关性疾病2 papers led
- Moyamoya disease烟雾病2 papers led
- Takayasu arteritis大动脉炎1 paper led
- Hepatic echinococcosis肝包虫病0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症52 papers led2 open trials led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led1 open trial led
- Fabry disease法布雷病1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病1 paper led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Myasthenia gravis, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Lymphangioleiomyomatosis, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 11 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.07%.
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Recruiting68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07760012
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led11
- Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma.
- Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation.
- Stereotactic radiotherapy with Gamma Master System® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.
- SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.
- Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients.
- CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker.
- Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma.
- Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.
- Allosteric regulation of the lid domain of PCK2 as a novel strategy for modulating mitochondrial dynamics.
- Advances in radiotherapy and immunity in hepatocellular carcinoma.
- Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.
All its trials on ClinicalTrials.gov, any status2
Cancer
Stomach cancer
胃癌Led 24 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2023-04
- Registry
- NCT06792162
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- Not yet recruitingEndoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
- Phase
- N/A
- Started
- 2019-03
- Registry
- NCT03857737
Age not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingOral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07552402
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan
- RecruitingStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06731478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led24
- Helicobacter pylori infection status and evolution of gastric cancer.
- Dynamic changes of host immune response during Helicobacter pylori-induced gastric cancer development.
- Luteolin improves precancerous conditions of the gastric mucosa by binding STAT3 and inhibiting LCN2 expression.
- Ultrasound-triggered topical oxygen delivery enhances synergistic sonodynamic and antibody therapies against hypoxic gastric cancer.
- Cmtm4 Deficiency Inhibits Helicobacter pylori-Induced Gastric Carcinogenesis.
- Raman spectroscopy and machine learning for early detection of gastric cancer and Helicobacter pylori with gastric juice.
- YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
- Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-κB/IL8 pathway.
- Machine learning models to predict submucosal invasion in early gastric cancer based on endoscopy features and standardized color metrics.
- Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
- Long-term outcomes of additional surgery versus non-gastrectomy treatment for early gastric cancer after non-curative endoscopic submucosal dissection: a meta-analysis.
- The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.
- Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
- Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
- Double contrast-enhanced ultrasound for the preoperative gross classification of gastric cancer: a comparison with multidetector computed tomography.
- Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer.
- Traditional Chinese medicine for precancerous lesions of gastric cancer: A review.
- Long-Term Outcome of Gastric Mild-Moderate Dysplasia: A Real-World Clinical Experience.
- Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
- Effect of Helicobacter pylori on immunotherapy is gaining more attention.
- Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
- Microbiome changes in the gastric mucosa and gastric juice in different histological stages of Helicobacter pylori-negative gastric cancers.
- Downregulation of FABP5 Suppresses the Proliferation and Induces the Apoptosis of Gastric Cancer Cells Through the Hippo Signaling Pathway.
- Endoscopic grading of gastric atrophy on risk assessment of gastric neoplasia: A systematic review and meta-analysis.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status13
- PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
- Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
- Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD
- Predictive Factors for Roux Stasis Syndrome
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Chordoma
脊索瘤Led 6 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 5.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality.
- SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas.
- Misdiagnosis of primary dumbbell chordoma of the cervical spine.
- Complications and local recurrence of chondrosarcoma and chordoma treated by total tumor resection in thoracic and lumbar spine.
- Hypoxia-Inducible Factor-1α (HIF-1α) as a Factor to Predict the Prognosis of Spinal Chordoma.
- Preliminary study of monoexponential, biexponential, and stretched-exponential models of diffusion-weighted MRI and diffusion kurtosis imaging on differential diagnosis of spinal metastases and chordoma.
Earlier papers (2016–2020)9
- Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.
- Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.
- Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
- [Anesthesia management of cervical chordoma resection: A case report].
- Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
- A brief review of chordomas: pathogenesis, prognostic factors and therapeutic targets.
- Radiofrequency ablation in gross total excision of cervical chordoma: ideas and technique.
- Prognostic Factors in Surgical Patients with Chordomas of the Cervical Spine: A Study of 52 Cases from a Single Institution.
- Morphological and dynamic contrast enhanced MR imaging features for the differentiation of chordoma and giant cell tumors in the Axial Skeleton.
Cancer
Osteosarcoma
骨肉瘤Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led7
- Arnicolide D Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells through PI3K/Akt/mTOR Pathway.
- Metabolic Landscape of Osteosarcoma: Reprogramming of Lactic Acid Metabolism and Metabolic Communication.
- Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma.
- The Dilemma of Balance between Benefits and Losses for Chondromyxoid Fibroma-like Osteosarcoma in Thoracic Spine with Azygos Tumor Thrombosis: A Case Report.
- Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.
- D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy.
- VPS34 regulates dynamin to determine the endocytosis of mitochondria-targeted zinc oxide nanoparticles in human osteosarcoma cells.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)9
- HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.
- Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.
- Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.
- Cross Talk Between Autophagy and Apoptosis Contributes to ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death.
- Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway.
- Renal Ewing's sarcoma/primitive neuroectodermal tumor: a case report and literature review.
- Recurrence Factors in Giant Cell Tumors of the Spine.
- Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.
- Reconstruction of the Upper Cervical Spine Using a Personalized 3D-Printed Vertebral Body in an Adolescent With Ewing Sarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Cancer
Neuroblastoma
神经母细胞瘤Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)3
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05565807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Phase
- Phase 4
- Started
- 2023-10
- Registry
- NCT06057402
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan
- RecruitingA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Phase
- Phase 4
- Started
- 2022-03
- Registry
- NCT05201781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingA Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2022-08
- Registry
- NCT05299424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2021-02
- Registry
- NCT04634552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model-Informed Precision Dosing for Chinese Population With Renal Insufficiency.
- Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
- Vertebral MRI-based radiomics model to differentiate multiple myeloma from metastases: influence of features number on logistic regression model performance.
- Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods.
- A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status32
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Ixazomib Rollover Study
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Moyamoya disease
烟雾病Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
Other diseases
Hepatic echinococcosis
肝包虫病Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Patient journey and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife) in China: a sequential exploratory mixed methods research protocol.
- Development of an Artificial Intelligence Model for Analyzing the Relationship between Imaging Features and Glucocorticoid Sensitivity in Idiopathic Interstitial Pneumonia.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status3
- Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
- Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 52 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 6.7%.
19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- Phase
- Phase 4
- Started
- 2023-01
- Registry
- NCT05923905
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingNatural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Not given
- Started
- 2019-11
- Registry
- NCT04454892
Age not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingA Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Registry
- NCT07082192
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingThe Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07118319
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led52
- A rare genetic variant in APEX1 is associated with familial amyotrophic lateral sclerosis with slow progression.
- Educational adjustments for the Chinese version of the Edinburgh Cognitive and Behavioral Screen (ECAS): establishing normative data.
- The contralateral co-movement test in a Chinese population with amyotrophic lateral sclerosis.
- Low CD3 level is a risk factor for amyotrophic lateral sclerosis: a Mendelian randomization study.
- Unveiling structural damage of the corpus callosum in amyotrophic lateral sclerosis through diffusion tensor imaging and spread direction perspectives.
- Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
- Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis.
- Characteristics of Neuromuscular Ultrasound in Patients with Amyotrophic Lateral Sclerosis.
- Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.
- Characteristics and influencing factors of pain in amyotrophic lateral sclerosis: a focus on symptom management.
- Two-step Mendelian randomization reveals a lipid-driven protective effect of type 2 diabetes on ALS.
- Concomitant presence of a novel ARPP21 variant and CNVs in Chinese familial amyotrophic lateral sclerosis-frontotemporal dementia patients.
- Amyotrophic Lateral Sclerosis With Concurrent LHON-associated m.14484T>C Mutation: A Case Report and Literature Review.
- The experience of pain symptoms in patients with amyotrophic lateral sclerosis: a qualitative study.
- Smell loss is associated with cognitive impairment in amyotrophic lateral sclerosis patients.
- Immune-mediated diseases are associated with a higher risk of ALS incidence: a prospective cohort study from the UK Biobank.
- Whole-Genome Sequencing Identified a Novel Mutation in the N-Terminal Domain of KIF5A in Chinese Patients with Familial Amyotrophic Lateral Sclerosis.
- Validation of the Center for Neurologic Study Bulbar Function Scale-Chinese version in a population with amyotrophic lateral sclerosis.
- Lower creatinine-to-cystatin c ratio associated with increased risk of incident amyotrophic lateral sclerosis in the prospective UK biobank cohort.
- The integrity of the corticospinal tract and corpus callosum, and the risk of ALS: univariable and multivariable Mendelian randomization.
- Neutrophils Are Associated with Higher Risk of Incident Amyotrophic Lateral Sclerosis in a BMI- and Age-Dependent Manner.
- Cost analysis of amyotrophic lateral-sclerosis management in China.
- Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.
- Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis.
- Neutrophils: a subgroup of neglected immune cells in ALS.
- A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis.
- An identical DCTN1 mutation in two Chinese siblings manifest as dHMN and ALS respectively: a case report.
- Human endogenous retrovirus K (HERV-K) env in neuronal extracellular vesicles: a new biomarker of motor neuron disease.
- Assessment of bidirectional relationships between 98 genera of the human gut microbiota and amyotrophic lateral sclerosis: a 2-sample Mendelian randomization study.
- Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis.
- Genotype-phenotype correlations in a chinese population with familial amyotrophic lateral sclerosis.
- Dietary-Derived Essential Nutrients and Amyotrophic Lateral Sclerosis: A Two-Sample Mendelian Randomization Study.
- Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study.
- Small fiber neuropathy for assessment of disease severity in amyotrophic lateral sclerosis: corneal confocal microscopy findings.
- Association between type 2 diabetes and amyotrophic lateral sclerosis.
- Amyotrophic lateral sclerosis: new era, new challenges.
- Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis.
- Induced pluripotent stem cell-derived motor neurons from amyotrophic lateral sclerosis (ALS) patients carrying different superoxide dismutase 1 mutations recapitulate pathological features of ALS.
- Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort.
- Trends in the clinical features of amyotrophic lateral sclerosis: A 14-year Chinese cohort study.
- Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.
- Daytime sleepiness might increase the risk of ALS: a 2-sample Mendelian randomization study.
- Validation of the pathogenic role of rare DNAJC7 variants in Chinese patients with amyotrophic lateral sclerosis.
- Physical activity and amyotrophic lateral sclerosis: a Mendelian randomization study.
- GLT8D1 may not be significant in Chinese sporadic amyotrophic lateral sclerosis patients.
- The complement C7 variant rs3792646 is associated with amyotrophic lateral sclerosis in a Han Chinese population.
- TBK1 variants in Chinese patients with amyotrophic lateral sclerosis.
- Leukocyte telomere length and amyotrophic lateral sclerosis: a Mendelian randomization study.
- Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up.
- Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression.
- Myoglobin: a new biomarker for spinal and bulbar muscular atrophy?
- A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations.
Chinese-language papers (not in the count)7
- [Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis].
- [Cortical thickness and cognitive impairment in patients with amyotrophic lateral sclerosis].
- [Genetic distribution in Chinese patients with hereditary peripheral neuropathy].
- [Cu/Zn superoxide dismutase and amyotrophic lateral sclerosis: a review of the current state of basic research and clinical trials].
- [Corneal confocal microscopy detects small-fiber neuropathy in patients with amyotrophic lateral sclerosis].
- [Rare variants of HSPB1 are probably associated with amyotrophic lateral sclerosis].
- [Association between rare UBQLN2 variants and amyotrophic lateral sclerosis in Chinese population].
Earlier papers (2016–2020)36
- The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China.
- Twelve-month duration as an appropriate criterion for flail arm syndrome.
- Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study.
- Reply to "Life Course Adiposity and Amyotrophic Lateral Sclerosis".
- Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.
- Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol.
- Anesthetic management of a parturient with amyotrophic lateral sclerosis undergoing cesarean section.
- Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study.
- Whole-exome sequencing identified novel KIF5A mutations in Chinese patients with amyotrophic lateral sclerosis and Charcot-Marie-Tooth type 2.
- Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients.
- Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.
- [Decremental responses to repetitive nerve stimulation at slow rates in amyotrophic lateral sclerosis].
- Cognitive and behavioral impairments in German and Chinese ALS populations - a post-hoc comparison of national study data.
- Vestibular evoked myogenic potentials and their clinical utility in patients with amyotrophic lateral sclerosis.
- Two rare variants of the ANXA11 gene identified in Chinese patients with amyotrophic lateral sclerosis.
- [Application value of motor unit number index in patients with amyotrophic lateral sclerosis].
- Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North America.
- Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015.
- The epidemiology and genetics of Amyotrophic lateral sclerosis in China.
- Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis.
- Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: re-evaluating the pathogenesis of TUBA4A in ALS.
- Using the Capture-Recapture Method to Estimate the Incidence of Amyotrophic Lateral Sclerosis in Beijing, China.
- A novel mutation of BICD2 gene associated with juvenile amyotrophic lateral sclerosis.
- Clinical Features of Isolated Bulbar Palsy of Amyotrophic Lateral Sclerosis in Chinese Population.
- Diets for Patients with Amyotrophic Lateral Sclerosis: Pay Attention to Nutritional Intervention.
- Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese.
- CHCHD10 mutations in patients with amyotrophic lateral sclerosis in Mainland China.
- DCTN1 gene analysis in Chinese patients with sporadic amyotrophic lateral sclerosis.
- No Evidence for Pathogenic Role of UBQLN2 Mutations in Sporadic Amyotrophic Lateral Sclerosis in the Mainland Chinese Population.
- Association Between Rectus Abdominis Denervation and Ventilation Dysfunction in Patients with Amyotrophic Lateral Sclerosis.
- Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.
- MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis.
- Two distinct clinical features and cognitive impairment in amyotrophic lateral sclerosis patients with TARDBP gene mutations in the Chinese population.
- The presence of spontaneous EMG activity in sternocleidomastoid is associated with ventilatory dysfunction in ALS.
- The Edinburgh Cognitive and Behavioural ALS Screen in a Chinese Amyotrophic Lateral Sclerosis Population.
- [Association of serum uric acid level with amyotrophic lateral sclerosis].
All its trials on ClinicalTrials.gov, any status25
- Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
- Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis
- Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis
- Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China
- Sleep Disorders and the Onset and Progression of ALS
- Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome
- Appetite and Related Factors in Patients With ALS
- Investigation on Home Care Needs of ALS Patients and Their Caregivers
- Efficacy and Safety of Nitrazine in the Treatment of ALS
- Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
- The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules
- Multimodal Brain Imaging Study
- Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis
- Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases
- Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis
- Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis
- Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis
- A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
- A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
- Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEffects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07822711
Age 6 years to 12 years (registered criteria)
Led by Peking University Third HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Earlier papers (2016–2020)3
All its trials on ClinicalTrials.gov, any status2
Other diseases
Fabry disease
法布雷病Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status2
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other linked evidence
Getting in touch
Name card to show staff or a driver
北京大学第三医院
Peking University Third Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.